Form 4: Lenz Therapeutics Executive Exercises Stock Options

Chief Commercial Officer of Lenz Therapeutics, Shawn Olsson, exercised stock options to acquire 3,333 shares of common stock at $2.08 per share.

Summary

• Shawn Olsson, Chief Commercial Officer at Lenz Therapeutics, exercised stock options on December 16, 2024.
• This transaction involved the acquisition of 3,333 shares of common stock at a price of $2.08 per share.
• The stock options were granted under the company's 2020 Equity Incentive Plan.
• The options vest over time, with 25% vesting after one year from the Vesting Commencement Date of April 26, 2021, and the remainder vesting monthly thereafter.
• Following the transaction, Mr. Olsson directly owns 64,641 derivative securities.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to executive compensation, which is generally a neutral to slightly positive event. The exercise of options suggests the executive's confidence in the company.

Positives

• The exercise of stock options by a key executive indicates confidence in the company's future prospects.
• The vesting schedule of the options aligns the executive's interests with the long-term performance of the company.

Industry Context

This is a standard transaction for a company that uses stock options as part of its executive compensation package. It is common for executives to exercise options as they vest.

Comparison to Industry Standards

• Stock option grants and vesting schedules are a common practice in the biotechnology industry, used to attract and retain talent.
• The vesting schedule described is typical, with a cliff vesting period followed by monthly vesting.
• The exercise price of $2.08 is specific to the company's valuation at the time of the grant.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it increases the number of shares outstanding, but it is a normal part of executive compensation.

Key Dates

Keywords

stock options, equity incentive plan, insider trading, executive compensation, Lenz Therapeutics, Shawn Olsson, common stock